4-Bromo-2,5-dimethoxyamphetamine

Identification

Name
4-Bromo-2,5-dimethoxyamphetamine
Accession Number
DB01484
Type
Small Molecule
Groups
Experimental, Illicit
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
32156-26-6
Weight
Average: 274.154
Monoisotopic: 273.036441408
Chemical Formula
C11H16BrNO2
InChI Key
FXMWUTGUCAKGQL-UHFFFAOYSA-N
InChI
InChI=1S/C11H16BrNO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3
IUPAC Name
1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine
SMILES
COC1=CC(Br)=C(OC)C=C1CC(C)N

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with 4-Bromo-2,5-dimethoxyamphetamine.
AcepromazineAcepromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.
AceprometazineAceprometazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.
AcetazolamideAcetazolamide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.
AcetophenazineAcetophenazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.
Acrivastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Acrivastine.
Alcaftadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Alcaftadine.
Alfentanil4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Alfentanil.
Alimemazine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Alimemazine.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
62065
PubChem Substance
46507989
ChemSpider
55902
BindingDB
50005257
ChEMBL
CHEMBL6607
IUPHAR
163
Guide to Pharmacology
GtP Drug Page

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.58HANSCH,C & LEO,AJ (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.0948 mg/mLALOGPS
logP2.53ALOGPS
logP2.26ChemAxon
logS-3.5ALOGPS
pKa (Strongest Basic)9.9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity64.25 m3·mol-1ChemAxon
Polarizability25.28 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9962
Blood Brain Barrier+0.9475
Caco-2 permeable+0.7137
P-glycoprotein substrateNon-substrate0.711
P-glycoprotein inhibitor INon-inhibitor0.804
P-glycoprotein inhibitor IINon-inhibitor0.9441
Renal organic cation transporterNon-inhibitor0.8015
CYP450 2C9 substrateNon-substrate0.8693
CYP450 2D6 substrateSubstrate0.6261
CYP450 3A4 substrateSubstrate0.5248
CYP450 1A2 substrateInhibitor0.8743
CYP450 2C9 inhibitorNon-inhibitor0.8389
CYP450 2D6 inhibitorInhibitor0.8451
CYP450 2C19 inhibitorNon-inhibitor0.7714
CYP450 3A4 inhibitorNon-inhibitor0.7737
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.5865
CarcinogenicityNon-carcinogens0.7668
BiodegradationNot ready biodegradable0.9808
Rat acute toxicity3.0047 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8956
hERG inhibition (predictor II)Non-inhibitor0.617
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Bromobenzenes / Aralkylamines / Alkyl aryl ethers / Aryl bromides / Organopnictogen compounds / Organobromides
show 2 more
Substituents
Amphetamine or derivatives / P-dimethoxybenzene / Dimethoxybenzene / Phenylpropane / Phenoxy compound / Anisole / Methoxybenzene / Phenol ether / Alkyl aryl ether / Bromobenzene
show 17 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on July 31, 2007 07:09 / Updated on August 02, 2018 04:36